We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Clinical Trial Confirms Potential of Candidate Antimyeloma Drug

By LabMedica International staff writers
Posted on 08 Sep 2015
Print article
Image: Molecular model of CD38 (Photo courtesy of Wikimedia Commons).
Image: Molecular model of CD38 (Photo courtesy of Wikimedia Commons).
The candidate drug daratumumab, which is a monoclonal antibody that targets the cell surface molecule CD38 (cluster of differentiation 38), was shown to be a safe and effective treatment for multiple myeloma in a combined phase I/II clinical trial.

CD38 is a 45 kDa, type II transmembrane glycoprotein that associates with cell-surface receptors in lipid rafts, regulates cytoplasmic calcium ion flux, and mediates signal transduction in lymphoid and myeloid cells. CD38 is highly and uniformly expressed on myeloma cells and is expressed at relatively low levels on normal lymphoid and myeloid cells and in some tissues of nonhematopoietic origin, which makes it a potential target in the treatment of myeloma.

Daratumumab (HuMax-CD38, Genmab), a human IgG1kappa monoclonal antibody, binds to a unique CD38 epitope. Preclinical studies showed that daratumumab induced target-cell killing of CD38-expressing tumor cells by means of multiple mechanisms, including complement-mediated and antibody-dependent cell-mediated cytotoxic effects, antibody-dependent cellular phagocytosis, apoptosis, and to a lesser extent, inhibition of the enzymatic activity of CD38. The anti-myeloma activity of daratumumab in preclinical studies prompted the initiation of a phase I/II study involving patients with relapsed myeloma or relapsed and refractory myeloma.

Investigators at the Dana-Farber Harvard Cancer Center (Boston, MA, USA) conducted the phase I/II study with a group of multiple myeloma patients who had received at least two prior lines of therapy and whose disease had relapsed and no longer responded to treatment. Following an initial phase in which the dose of the drug was gradually increased, 72 patients were enrolled in the second phase, in which two doses were tested at different administration schedules - weekly, twice monthly, and monthly - for up to two years.

Results published in the August 26, 2015, online edition of the New England Journal of Medicine revealed that the overall response rate was 36% in the cohort that received 16 milligrams per kilogram (15 patients had a partial response or better, including two with a complete response and two with a very good partial response) and 10% in the cohort that received eight milligrams per kilogram (three had a partial response). In the cohort that received 16 milligrams per kilogram, the median progression-free survival was 5.6 months, and 65% of the patients who had a response did not have progression at 12 months.

Reactions to the drug in the phase II trial were mild with no dose-dependent adverse events. The most common adverse events in about 5% of patients were pneumonia and thrombocytopenia.

"As a single-agent therapy, daratumumab showed significant promise against difficult-to-treat disease in our patients with advanced myeloma and who have few other therapeutic options," said senior author Dr. Paul Richardson, professor of medicine at the Dana-Farber Harvard Cancer Center. "Because it targets a key receptor and works through different mechanisms than other available agents, it clearly has merited comprehensive testing in larger clinical trials. Preliminary results from these studies have been very encouraging."

Related Links:

Dana-Farber Harvard Cancer Center

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
POCT Fluorescent Immunoassay Analyzer
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article


Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more


view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more


view channel
Image: A false color scanning election micrograph of lung cancer cells grown in culture (Photo courtesy of Anne Weston)

AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell

Current strategies for matching cancer patients with specific treatments often depend on bulk sequencing of tumor DNA and RNA, which provides an average profile from all cells within a tumor sample.... Read more


view channel
Image: Microscope image showing human colorectal cancer tumor with Fusobacterium nucleatum stained in a red-purple color (Photo courtesy of Fred Hutch Cancer Center)

Mouth Bacteria Test Could Predict Colon Cancer Progression

Colon cancer, a relatively common but challenging disease to diagnose, requires confirmation through a colonoscopy or surgery. Recently, there has been a worrying increase in colon cancer rates among younger... Read more


view channel
Image: Fingertip blood sample collection on the Babson Handwarmer (Photo courtesy of Babson Diagnostics)

Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection

Warming the hand is an effective way to facilitate blood collection from a fingertip, yet off-the-shelf solutions often do not fulfill laboratory requirements. Now, a unique hand-warming technology has... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.